@article {109, title = {Comparative Analysis of Alternate Day and Daily Regimen of Atorvastatin in Dyslipidaemic South Indian Patients}, journal = {International Journal of Pharmacology and Clinical Sciences}, volume = {5}, year = {2016}, month = {December 2016}, pages = {97-102}, type = {Research Article}, chapter = {97}, abstract = {

Background: Atorvastatin is the most commonly used drug for the treatment of dyslipidaemia. Long term administration of statins helps in the reduction of cardiovascular morbidity and mortality associated with dyslipidaemia. Number of studies have shown that alternate day dosing of statins is efficacious and safe alternative to daily dosing. Objectives: To compare the efficacy and tolerability of daily and alternate day regimen of Atorvastatin in the treatment of na{\"\i}ve dyslipidaemic South Indian patients. Materials and Methods: It is an open labeled, prospective, parallel, comparative interventional study. Ninety patients satisfying the inclusion criteria were randomized in to group 1 (n=45) and group 2 (n=45) and received atorvastatin 10 mg daily and alternate days respectively for 3 months. Pretreatment and post treatment anthropometric measurements, biochemical and lipid parameters were recorded. Patients were followed at fortnightly intervals for 3 months to check the patient compliance and adherence to treatment. Data were analyzed by suitable statistical methods. Results: There was a statistically significant reduction of total cholesterol, triglycerides, LDL, VLDL and increase of HDL cholesterol in both groups. Post treatment between group comparison shows a significantly higher reduction of LDL in group 1 than group 2 patients. All other lipid parameters were significantly similar between the groups at 12 weeks follow-up. Daily and alternate day treatment were well tolerated by the patients of both the group and there was no untoward incident during the study period. Conclusion: Alternate day administration of atorvastatin causes a beneficial alternation of lipid parameters which helps in reducing the cost and adverse effects.

}, keywords = {Adverse events, Alternate day, Atherosclerosis, Atorvastatin, Hyperlipidaemia}, doi = {10.5530/ijpcs.5.4.1}, author = {Shanmugasundaram Rajamani and Maharani Balagurumoorthy} } @article {89, title = {Comparative Study of Atorvastatin and Rosuvastatin in Combination with Fenofibrate in Mixed Hyperlipidemia}, journal = {International Journal of Pharmacology and Clinical Sciences}, volume = {5}, year = {2016}, month = {March 2016}, pages = {25-31}, type = {Research Articles}, chapter = {25}, abstract = {

Aim: To compare the effects of Atorvastatin and Rosuvastatin in combination with fenofibrate in patients with mixed Hyperlipidemia. Materials and Methods: It was an open label, randomized, parallel group, comparative, prospective clinical study. A total of 70 subjects diagnosed with mixed hyperlipidemia were screened and were randomly allocated into two groups of thirty each. Initial readings of lipid levels like TC, TG, HDL, LDL and VLDL for both the groups were taken as baseline values. Then, Group I received Tab Atorvastatin 10 mg + Fenofibrate 160 mg and Group II received Tab Rosuvastatin 10 mg+ Fenofibrate 160 mg once a day at night for 12 weeks. Patients were assessed after 12 weeks and their Lipid profile was done. Results: Patients who received a combination of atorvastatin with fenofibrate had a reduction of Total cholesterol by 39\%, Triglycerides by 47\%, LDL-C by 50\% and VLDL-C by 35\% respectively. In group treated with combination of rosuvastatin with fenofibrate there was a decrease in TC by 54\%, TGs by 58\%, LDL-C by 52\% and VLDL-C by 56\% respectively. At the same time, HDL-C levels were increased by 14\% in the group treated with rosuvastatin with fenofibrate as compared to atorvastatin with fenofibrate treated group which increased the HDL-C levels by 6\%. Conclusion: Both the treatment regimens significantly decreased TC, TG, LDL-C, VLDL-C, but the reduction was more and statistically significant in Rosuvastatin and fenofibrate combination group when compared with atorvastatin and fenofibrate treated group at the end of 12 weeks.

}, keywords = {Atherosclerosis, Cholesterol, Heart, Lipoprotein, Statins}, doi = {10.5530/ijpcs.5.1.5}, author = {Rohit Dixit and Shankar Jagan} } @article {185, title = {Folic acid Level and Lipid Profile in Epilepsy Patients on Antiepileptic Drug Treatment}, journal = {International Journal of Pharmacology and Clinical Sciences,}, volume = {1}, year = {2012}, month = {Dec 2012}, pages = {91-96}, type = {Research Article}, chapter = {91}, abstract = {

Background:\ Folic acid deficiency occurs in some epileptic patients on long term treatment with enzyme inducing antiepileptic drug (AED) particularly phenytoin and this may lead to the development of atherosclerosis due to the lipid profile alteration.\ Objective:\ The present study was planned to investigate folic acid level and lipid profile among patients with epilepsy on antiepileptic drug treatment.\ Materials and Methods:\ A 25-week, prospective study was conducted in 250 bedded private hospital, Salem, Tamil Nadu, India. In this study, an attempt was made to compare the folic acid level, lipid profile and atherosclerotic risk including Framingham risk score between the normal healthy volunteers (Control), patients with newly diagnosed cases of epilepsy (Supercontrol) and patients with more than one year of antiepileptic drug treatment (Cases).\ Results:\ Folic acid level (in ng/dl) was found to be lower in cases (7.26 {\textpm} 2.98) than control (12.69 {\textpm} 5.64) and super control (9.35 {\textpm} 2.73) - the difference was statistically significant (p\<0.05). Normal total cholesterol (TC) level (162.0 {\textpm} 23.22 mg/dl) and normal very low density lipoprotein (VLDL) level (40.5 {\textpm} 12.89 mg/dl) was observed in cases. But decrease in high density lipoprotein (HDL) level (36.5 {\textpm} 12.45 mg/dl), elevated triglycerides (TGs) level (202.5 {\textpm} 64.44 mg/dl) was noted in cases and the difference was found to be significant (p\<0.05) as compared to control and su-percontrol. TC/HDL ratio, LDL/HDL ratio and TG/HDL ratio were increased in cases when compared with control and supercontrol. Framingham risk score reveals slightly higher risk in cases as compared to control and supercontrol.\ Conclusion:\ The result of this study reinforces the results of previous reports in terms of folic acid deficiency with AED treatment and the correlation between folic acid deficiency and cardiovascular risk needs to be established.

}, keywords = {Antiepileptic Drug, Atherosclerosis, Folic acid, Lipid Profile}, author = {A.Palanisamy and M.Arifa and M.P.Narmadha and N.N.Rajendran} }